May 09, 2024
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 08, 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Apr 03, 2024
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Apr 01, 2024
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Apr 01, 2024
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Jan 18, 2024
Surrozen Provides Corporate Update on Clinical Programs